Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Total Non-Current Liabilities (2020 - 2025)

Historic Total Non-Current Liabilities for Apellis Pharmaceuticals (APLS) over the last 6 years, with Q3 2025 value amounting to $654.3 million.

  • Apellis Pharmaceuticals' Total Non-Current Liabilities fell 9.44% to $654.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $654.3 million, marking a year-over-year decrease of 9.44%. This contributed to the annual value of $648.5 million for FY2024, which is 956.97% up from last year.
  • Apellis Pharmaceuticals' Total Non-Current Liabilities amounted to $654.3 million in Q3 2025, which was down 9.44% from $663.0 million recorded in Q2 2025.
  • Apellis Pharmaceuticals' Total Non-Current Liabilities' 5-year high stood at $682.4 million during Q1 2022, with a 5-year trough of $302.0 million in Q3 2021.
  • Its 5-year average for Total Non-Current Liabilities is $576.7 million, with a median of $588.4 million in 2023.
  • The largest annual percentage gain for Apellis Pharmaceuticals' Total Non-Current Liabilities in the last 5 years was 13693.18% (2021), contrasted with its biggest fall of 3272.9% (2021).
  • Apellis Pharmaceuticals' Total Non-Current Liabilities (Quarter) stood at $338.0 million in 2021, then surged by 66.75% to $563.5 million in 2022, then rose by 5.03% to $591.9 million in 2023, then grew by 9.57% to $648.5 million in 2024, then increased by 0.89% to $654.3 million in 2025.
  • Its Total Non-Current Liabilities was $654.3 million in Q3 2025, compared to $663.0 million in Q2 2025 and $641.0 million in Q1 2025.